NASDAQ:INMD

InMode - INMD Stock Forecast, Price & News

$37.10

+0.12 (+0.32%)

(As of 08/15/2022 12:00 AM ET)

Add

Compare

Today's Range: $36.34
▼
$37.49
50-Day Range: $21.45
▼
$38.27
52-Week Range: $20.60
▼
$99.27

Volume: 845,545 shs
Average Volume: 2.07 million shs
Market Capitalization: $3.09 billion

P/E Ratio: 18.46
Dividend Yield: N/A
Price Target: $55.60

InMode MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 49.9% Upside
$55.60 Price Target
Short Interest: Healthy
8.52% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.80
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

427th out of 1,125 stocks

Electromedical Equipment Industry

9th out of 24 stocks

3.5

Analyst's Opinion

Consensus Rating
InMode has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $55.60, InMode has a forecasted upside of 49.9% from its current price of $37.10.
Amount of Analyst Coverage
InMode has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
8.52% of the outstanding shares of InMode have been sold short.
Short Interest Ratio / Days to Cover
InMode has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in InMode has recently increased by 2.75%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
InMode does not currently pay a dividend.
Dividend Growth
InMode does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INMD.

3.8

News and Social Media Coverage

News Sentiment
InMode has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for InMode this week, compared to 5 articles on an average week.
Search Interest
59 people have searched for INMD on MarketBeat in the last 30 days. This is an increase of 48% compared to the previous 30 days.
MarketBeat Follows
22 people have added InMode to their MarketBeat watchlist in the last 30 days. This is an increase of 47% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, InMode insiders have not sold or bought any company stock.
Percentage Held by Institutions
53.58% of the stock of InMode is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of InMode is 18.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.80.
Price to Earnings Ratio vs. Sector
The P/E ratio of InMode is 18.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 123.45.
Price to Book Value per Share Ratio
InMode has a P/B Ratio of 7.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About InMode (NASDAQ:INMD) Stock

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on INMD shares. Canaccord Genuity Group reduced their target price on InMode from $50.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday, June 30th. Needham & Company LLC raised their price target on InMode from $58.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, July 29th. Robert W. Baird raised their price target on InMode from $44.00 to $53.00 in a research note on Friday, July 29th. Canaccord Genuity Group cut their price target on InMode from $50.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday, June 30th. Finally, TheStreet upgraded InMode from a "d+" rating to a "b-" rating in a research note on Tuesday, August 9th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $63.00.

InMode Stock Performance

INMD traded up $0.12 on Monday, hitting $37.10. The company had a trading volume of 845,623 shares, compared to its average volume of 2,067,781. The stock has a market capitalization of $3.09 billion, a price-to-earnings ratio of 18.46 and a beta of 2.32. The stock has a fifty day moving average price of $27.49 and a 200-day moving average price of $32.25. InMode has a 12-month low of $20.60 and a 12-month high of $99.27.

InMode (NASDAQ:INMD - Get Rating) last released its earnings results on Thursday, July 28th. The healthcare company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.51 by $0.08. InMode had a return on equity of 41.50% and a net margin of 42.66%. The firm had revenue of $113.55 million during the quarter, compared to the consensus estimate of $103.00 million. During the same quarter in the previous year, the company posted $1.02 earnings per share. The company's revenue was up 30.0% compared to the same quarter last year.

Receive INMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMode and its competitors with MarketBeat's FREE daily newsletter.

INMD Stock News Headlines

August 16, 2022 | americanbankingnews.com

Analysts Set InMode Ltd. (NASDAQ:INMD) Target Price at $63.00

August 15, 2022 | nasdaq.com

Is There An Opportunity With MaxLinear, Inc.'s (NASDAQ:MXL) 41% Undervaluation? - Nasdaq

August 15, 2022 | nasdaq.com

Possible bearish signals as AEye, Inc. (NASDAQ:LIDR) insiders disposed of US$571k worth of stock - Nasdaq

August 12, 2022 | americanbankingnews.com

InMode (NASDAQ:INMD) Lifted to "B-" at TheStreet

August 8, 2022 | benzinga.com

InMode to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1-on-1 Conference - Benzinga

August 8, 2022 | finance.yahoo.com

InMode to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1-on-1 Conference

August 5, 2022 | nasdaq.com

This Beaten-Down Growth Stock Has Significant Upside Potential. Time to Buy? - Nasdaq

August 5, 2022 | finance.yahoo.com

This Beaten-Down Growth Stock Has Significant Upside Potential. Time to Buy?

August 5, 2022 | markets.businessinsider.com

Jim Cramer: 'I Am No Longer A Huge Crypto Guy'

August 4, 2022 | finance.yahoo.com

Are Investors Undervaluing InMode Ltd. (NASDAQ:INMD) By 50%?

August 3, 2022 | fool.com

Here's Why InMode Stock Jumped 48% in July - The Motley Fool

August 3, 2022 | finance.yahoo.com

Here's Why InMode Stock Jumped 48% in July

August 2, 2022 | seekingalpha.com

InMode: Alpha Long-Term Growth - Playing Insurance Game Next - Seeking Alpha

August 1, 2022 | americanbankingnews.com

InMode (NASDAQ:INMD) Price Target Raised to $60.00

July 29, 2022 | finance.yahoo.com

Liposuction Surgery Devices Global Market Report 2022 - Yahoo Finance

July 28, 2022 | fool.com

InMode Ltd. (INMD) Q2 2022 Earnings Call Transcript

July 28, 2022 | investing.com

InMode Ltd. Tops Q2 EPS by 8c By Investing.com - Investing.com

July 28, 2022 | fool.com

Here's Why InMode Stock Surged Today - The Motley Fool

July 28, 2022 | finance.yahoo.com

Here's Why InMode Stock Surged Today

July 28, 2022 | seekingalpha.com

InMode Ltd. (INMD) CEO Moshe Mizrahy on Q2 2022 Results - Earnings Call Transcript

July 28, 2022 | seekingalpha.com

InMode Non-GAAP EPS of $0.59 beats by $0.08, revenue of $113.55M beats by $10.55M (NASDAQ:INMD) - Seeking Alpha

July 28, 2022 | finance.yahoo.com

InMode Reports Second Quarter 2022 Financial Results; Record Quarterly Revenue of $113.5M, Represents 30% Year-Over-Year Growth

July 27, 2022 | seekingalpha.com

InMode Q2 2022 Earnings Preview (NASDAQ:INMD) - Seeking Alpha

July 25, 2022 | seekingalpha.com

InMode Set To Outperform Going Forward, We Join The Bull Camp

July 24, 2022 | americanbankingnews.com

Movano (NASDAQ:MOVE) vs. InMode (NASDAQ:INMD) Critical Analysis

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive INMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMode and its competitors with MarketBeat's FREE daily newsletter.

INMD Company Calendar

Last Earnings: 7/28/2022
Today: 8/15/2022
Next Earnings (Estimated): 10/25/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INMD
CUSIP: N/A
CIK: 885988
Web: www.inmodemd.com
Phone: 972-4909-7470
Fax: N/A
Employees: 362
Year Founded: 2008

Price Target and Rating

Average Stock Price Forecast: $55.60
High Stock Price Forecast: $85.00
Low Stock Price Forecast: $40.00
Forecasted Upside/Downside: +49.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.01
Trailing P/E Ratio: 18.46
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $164.97 million
Net Margins: 42.66%
Pretax Margin: 45.25%
Return on Equity: 41.50%
Return on Assets: 35.91%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.78
Quick Ratio: 8.27

Sales & Book Value

Annual Sales: $357.57 million
Price / Sales: 8.64
Cash Flow: $1.99 per share
Price / Cash Flow: 18.67
Book Value: $5.00 per share
Price / Book: 7.42

Miscellaneous

Outstanding Shares: 83,241,000
Free Float: N/A
Market Cap: $3.09 billion
Optionable: Not Optionable
Beta: 2.32

Social Links

Key Executives

Mr. Yair Malca (Age 44)
Chief Financial Officer
Comp: $525k
Mr. Alon Yaari
VP of Operations
Ms. Nava Tal-Launer
Chief Information Officer
Mr. Shakil Lakhani (Age 39)
Pres of North America
Comp: $2.67M
Dr. Spero Theodorou M.D. (Age 50)
Chief Medical Officer
Comp: $1.84M
Mr. Moshe Mizrahy (Age 69)
Chairman & CEO
Dr. Michael Kreindel (Age 54)
CTO & Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INMD Stock - Frequently Asked Questions

Should I buy or sell InMode stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INMD shares.
View INMD analyst ratings or view top-rated stocks.
What is InMode's stock price forecast for 2022?: 5 Wall Street research analysts have issued 12-month target prices for InMode's stock. Their INMD share price forecasts range from $40.00 to $85.00. On average, they expect the company's stock price to reach $55.60 in the next year. This suggests a possible upside of 49.9% from the stock's current price.
View analysts price targets for INMD or view top-rated stocks among Wall Street analysts.
How have INMD shares performed in 2022?: InMode's stock was trading at $70.58 on January 1st, 2022. Since then, INMD shares have decreased by 47.4% and is now trading at $37.10.
View the best growth stocks for 2022 here.
When is InMode's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 25th 2022.
View our INMD earnings forecast.
How were InMode's earnings last quarter?: InMode Ltd. (NASDAQ:INMD) posted its earnings results on Thursday, July, 28th. The healthcare company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.08. The healthcare company earned $113.55 million during the quarter, compared to analysts' expectations of $103 million. InMode had a net margin of 42.66% and a trailing twelve-month return on equity of 41.50%. The company's quarterly revenue was up 30.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.02 earnings per share.
When did InMode's stock split?: InMode's stock split on the morning of Thursday, September 30th 2021. The 2-1 split was announced on Friday, September 17th 2021. The newly created shares were payable to shareholders after the market closes on Monday, September 27th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.
What guidance has InMode issued on next quarter's earnings?: InMode updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of $2.11-$2.16 for the period, compared to the consensus estimate of $2.08. The company issued revenue guidance of $425.00 million-$435.00 million, compared to the consensus revenue estimate of $425.36 million.
What is Moshe Mizrahy's approval rating as InMode's CEO?: 1 employees have rated InMode Chief Executive Officer Moshe Mizrahy on Glassdoor.com. Moshe Mizrahy has an approval rating of 100% among the company's employees. This puts Moshe Mizrahy in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of InMode own?: Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), DocuSign (DOCU) and PayPal (PYPL).
When did InMode IPO?: (INMD) raised $75 million in an IPO on Thursday, August 8th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.
What is InMode's stock symbol?: InMode trades on the NASDAQ under the ticker symbol "INMD."
Who are InMode's major shareholders?: InMode's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.72%), William Blair Investment Management LLC (2.27%), Noked Israel Ltd (1.87%), Meitav Dash Investments Ltd. (1.72%), Harel Insurance Investments & Financial Services Ltd. (0.80%) and Ibex Investors LLC (0.78%).
How do I buy shares of InMode?: Shares of INMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is InMode's stock price today?: One share of INMD stock can currently be purchased for approximately $37.10.
How much money does InMode make?: InMode (NASDAQ:INMD) has a market capitalization of $3.09 billion and generates $357.57 million in revenue each year. The healthcare company earns $164.97 million in net income (profit) each year or $2.01 on an earnings per share basis.
How many employees does InMode have?: The company employs 362 workers across the globe.
Does InMode have any subsidiaries?: The following companies are subsidiares of InMode: Guangzhou InMode Medical Technology Ltd., InMode Asia Limited., InMode India Private Limited, InMode Japan KK, InMode M.D. Ltd., Invasix Corp., Invasix Iberia S.L., Invasix Inc., and Invasix UK Ltd..
Read More
When was InMode founded?: InMode was founded in 2008.
How can I contact InMode?: InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The official website for the company is www.inmodemd.com. The healthcare company can be reached via phone at 972-4909-7470 or via email at ir@inmodemd.com.

This page (NASDAQ:INMD) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

InMode - INMD Stock Forecast, Price & News

InMode MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month